Dr. Tian Yi Zhang, MD

Dr. Zhang practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Zhang's NPI, 1760771737, was assigned on March 30, 2011. Dr. Zhang graduated from Spencer Fox Eccles School of Medicine in 2011. Dr. Zhang's California license number on file is A130597.

Dr. Zhang's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Zhang's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. Zhang is also affiliated with William P. Clements Jr. University Hospital. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Zhang to 2 more hospitals and 1 medical group, each named with a free account. Dr. Zhang's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zhang practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Zhang's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dmand AI has Dr. Zhang's licenses on file in 2 states: California and Utah.

Dmand AI lists chronic anemia, chronic leukemia, multiple myeloma, neutropenia and purpura and thrombocytopenia among the conditions Dr. Zhang treats.

CMS data shows 514 Medicare services from Dr. Zhang across 6 procedure codes in 2024, for 139 Medicare patients. Medicare paid $58,342 for them.

CMS counts 139 Medicare patients who saw Dr. Zhang in 2024. The largest group is 65 to 74, with 61 patients. 73% of them have high cholesterol, and 71% have high blood pressure. 24% are also on Medicaid. Their average risk score is 3.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zhang's median patient age at 63, with 51% women.

In 2024, Dr. Zhang wrote 139 Medicare Part D claims for 35 patients. 43% of them were for generic drugs. CMS names the drug for 56 of them, across 2 drugs with 11 or more claims each, at $198,230 in total drug cost. In 2023, CMS named 41 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Zhang for performance year 2024, reported as part of a group. Dr. Zhang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zhang as offering telehealth.

Dmand AI links 17 papers to Dr. Zhang, published from 2014 to 2025. 2020 was the busiest year, with 3. The most frequent topics are Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic and Sulfonamides. Dr. Zhang has published most often in Leukemia. Dr. Zhang's most frequent co-authors are Ravindra Majeti, MD, Gabriel Noah Mannis, MD and Ritika Dutta.

CMS Open Payments shows 28 general payments to Dr. Zhang from 10 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 61% of the total. Rigel Pharmaceuticals, Inc. paid the most, $5,725.

Dr. Zhang graduated from Spencer Fox Eccles School of Medicine in 2011.

Dr. Zhang is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.